The prohibition of glucocorticoids, such as prednisone, in competitive athletics stems from two primary concerns: their potential to artificially enhance performance and their associated health risks. These synthetic corticosteroids possess powerful anti-inflammatory and immunosuppressant properties. While therapeutically valuable for managing various medical conditions, their use in a sporting context raises significant ethical and physiological issues.
Glucocorticoids can mask pain, allowing athletes to train harder and longer than they normally could, potentially beyond their body’s natural limits. This pain masking effect can lead to increased risk of injury, as the athlete may not recognize or respond appropriately to warning signs. Furthermore, these substances have been shown to exhibit anabolic effects, albeit less potent than anabolic steroids. They can promote muscle glycogen storage and potentially improve mood and alertness, leading to a perceived performance advantage. Historically, the misuse of these substances has been observed across various sports, prompting regulatory bodies to take action.
